Conflict of Interest Disclosures: Dr Ross reported receiving grants from the US Food and Drug Administration, Johnson & Johnson, Medical Devices Innovation Consortium, the Agency for Healthcare Research and Quality, National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute, and Arnold Ventures outside the submitted work and serving an expert witness in a suit against Biogen Inc (settled September 2022). Dr Jastreboff reported receiving trial funding to her institution from Amgen, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Rhythm Pharmaceuticals and receiving personal fees for serving on scientific advisory boards from Amgen, AstraZeneca, Biohaven, Boehringer Ingelheim, Eli Lilly, Intellihealth, Novo Nordisk, Pfizer, Regeneron, Roche, Scholar Rock, Structure Therapeutics, Syntis Bio, Terns, WeightWatchers, and Zealand outside the submitted work. Dr Meeker reported receiving a grant (UL1TR001863) from the National Center for Advancing Translational Sciences during the conduct of the study. Dr Krumholz reported receiving options for Element Science and Identifeye for advisory roles; receiving payments from F-Prime for advisory roles; that he is a cofounder of, and held equity in, Hugo Health; that he is a cofounder of, and holds equity in, Refactor Health and ENSIGHT-AI; and that he is associated with research contracts through Yale University from Janssen, Kenvue, Novartis, and Pfizer. Dr Lu reported receiving support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (awards R01HL69954 and R01HL169171), the Patient-Centered Outcomes Research Institute (award HM-2022C2-28354), Sentara Research Foundation, and Novartis through Yale University outside the submitted work. No other disclosures were reported.